Eli Lilly tops new biopharma ranking on launch success, development speed Read more →
Incyte ditches phase 1-stage JAK inhibitor to pursue next-gen options Read more →
Altimmune’s next-gen GLP-1 curbs heavy drinking in ‘unequivocal’ ph. 2 alcohol use disorder win Read more →
This content is password-protected. To view it, please enter the password below.
Password:
